| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 10-Q |
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 16 Oct 2026 | SCHEDULE 13D/A |
| 15 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE O... |
| 18 Aug 2026 |
Form 4: Lettmann Jason, Director
Sold 2,230 shares ($4.3K) |
| 18 Aug 2026 |
Form 4: Wong Shelly, SVP, FINANCE AND CAO
Sold 573 shares ($1.11K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer – |
| 27 Jul 2026 | SCHEDULE 13G |
| 06 Jul 2026 |
Form 4: Wong Shelly, SVP, FINANCE AND CAO
Sold 1,404 shares ($2.86K) |
| 30 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more
Strengthens Leadership with Veteran Executives with Decades of Industry Experience |
| 26 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
On June 25, 2026, ALX Oncology Holdings Inc., a Delaware corporation (the “Company”), entered into a loan and security agreement (the “Loan Agreement”) among HSBC Ventures USA Inc., as lender, ALX Oncology Inc., a Delaware corporation (“... |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
ALX Oncology Holdings Inc. (the “Company”) held its Annual Meeting of stockholders (the “Annual Meeting”) on June 10, 2026. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below. |
| 27 May 2026 | SCHEDULE 13D/A |
| 15 May 2026 | SCHEDULE 13G/A |
| 15 May 2026 | SCHEDULE 13G/A |
| 08 May 2026 | 10-Q |
| 08 May 2026 |
8-K: Results of Operations and Financial Condition
- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination - |
| 28 Apr 2026 | SCHEDULE 13G/A |
Loading...